ALPHARMA INC.

INDEX

ALPHARMA INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands)

See notes to the consolidated financial statements.

ALPHARMA INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In thousands of dollars, except per share data)
(Unaudited)

See notes to the consolidated financial statements.

ALPHARMA INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of dollars)
(Unaudited)

See notes to the consolidated financial statements.

1.    General

     The accompanying consolidated financial statements include all adjustments which are, in the opinion of management, considered necessary for a fair presentation of the results of operations and financial position for the periods presented. These financial statements should be read in conjunction with the consolidated financial statements of Alpharma Inc. and its Subsidiaries ("the Company") included in the Company's 2006 Annual Report on Form 10-K. The reported results for the three and nine month periods ended September 30, 2007 are not necessarily indicative of the results to be expected for the full year. Certain amounts have been reclassified to conform with current presentations.

Basis of Presentation:

2.    Discontinued Operations

Sale of the Generics Business - On December 19, 2005, the Company sold its worldwide human generic pharmaceutical business to Actavis Group hf ("Actavis") on a debt-free and cash-free basis, for $810,000.

     Sale of the ParMed Business - On March 31, 2006, the Company sold its generic pharmaceutical telemarketing distribution business, ParMed for $40,100 in cash. The net after-tax gain on the sale, $25,814, was reported in 2006 results from discontinued operations, along with adjustments related to the disposal of the Generics Business which was sold in December 2005.

The following table details selected financial information for ParMed, which is classified as a discontinued operation:

3. Acquisitions and Alliances

     In July 2007, the Company announced it had completed its previously disclosed alliance agreements with Zhejiang Hisun Pharmaceutical Co., Ltd ("Hisun") that, over the next several years, will enable the Company's Active Pharmaceutical Ingredients ("API") business to significantly expand its manufacturing capacity for one of its major active pharmaceutical ingredients, vancomycin, subject to the receipt of required FDA and European regulatory approvals. Since 2006, Alpharma has purchased vancomycin from Hisun pending the completion of the construction and regulatory approval process of a new vancomycin manufacturing facility in Taizhou, China. The new facility, which will be owned and operated by Alpharma, is expected to be completed in 2008. During the three and nine months ended September 30, 2007, the Company invested approximately $6,300 and $6,900, respectively in capital expenditures at the Taizhou facility.

     In June 2007, the Company acquired certain assets of Yantai JinHai Pharmaceutical Co. Ltd. ("Yantai") located in Yantai City, Shandong Province. The Company's Animal Health ("AH") business plans to utilize this site to blend products it currently produces in its U.S. facilities and sells in Asia. The purchase of these assets is expected to provide supply chain flexibility, and expand the Company's regulatory base in Asia. The acquisition includes product registrations that the Company plans to utilize to expand its Asian product offering.

     In April 2007, the Company acquired assets of Shenzhou Tongde Pharmaceutical Co. Ltd ("Tongde") in Shenzhou City, China. Tongde was a supplier to the Company's AH business and manufactures and markets zinc bacitracin. Tongde's 2006 annual sales approximated $5,000. Following the acquisition, the Company continues to support the current customer base of Tongde while also exporting the product to other markets.

     The purchase price for the acquisitions of Yantai and Tongde totaled approximately $6,900; $4,800 of which was paid in the second quarter of 2007, with the remainder paid upon resolution of certain contractual conditions in the third quarter of 2007.

4.     License and Collaboration Agreements

Institut Biochimique SA ("IBSA")

     In September 2007, the Company's affiliate, Alpharma Pharmaceuticals LLC, closed on two license and distribution agreements (the "IBSA License and Distribution Agreements") with IBSA, a privately-owned, global pharmaceutical company headquartered in Lugano, Switzerland. The agreements have a ten year term, with automatic renewal options, and provide the Company with the exclusive license and distribution rights to market: 1) the Flector^® Patch and 2) Tirosint^® (synthetic levothyroxine sodium) gel capsules, in the United States. The Flector^® Patch, which was approved in the U.S. by the FDA in January 2007, delivers the anti-inflammatory and analgesic effects of patent-protected diclofenac epolamine through a topical patch, and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. Tirosint^® was approved by the FDA in October 2006 and is indicated for thyroid hormone replacement therapy.

     The terms of the IBSA License and Distribution Agreements called for a total of $100,000 in upfront payments upon closing. The Company paid IBSA $5,000 of this amount during the second quarter of 2007 and the remaining $95,000 at closing, in September 2007. In addition, on October 3, 2007, in accordance with the terms of the Flector^® Patch agreement, the Company issued to IBSA a warrant for the purchase of up to one million shares of the Company's Class A common stock. These stock warrants were issued with a $35 strike price and a three-year term, through August 16, 2010.

     Under the terms of the IBSA License and Distribution Agreements, the Company must undertake to launch the Flector^® Patch and Tirosint^® gel capsules within nine and twelve months, respectively, from the closing date of the agreements. The Company is targeting a U.S. launch of the Flector^® Patch in early 2008, and is currently evaluating the Tirosint^® launch strategy.

     Commercial supply of the Flector^® Patch will be provided by IBSA, at contractually determined prices, through a manufacturing agreement IBSA has with a Japanese supplier. It is expected that IBSA will supply the Tirosint^® product, at contractually determined prices, from its own manufacturing facility.

     The IBSA License and Distribution Agreements include certain annual minimum purchase commitments for both the Flector^® Patch and Tirosint^® gel capsules. The minimum commitments increase each year over the first three years from product launch and remain at year three levels (or, in the case of Tirosint^® agreement, at the slightly reduced year four level) for the remaining years of the agreements.

     The $100,000 cash payments to IBSA and transaction related costs have been capitalized as an addition to intangible assets as of September 30, 2007. The Black-Scholes value of the stock warrants (approximately $2,000) will be capitalized in the fourth quarter of 2007 as an addition to intangible assets. These intangible assets will be amortized over the estimated commercial lives of the products, using a sales-activity-based methodology.

5.     Liquidity and Capital Resources

     At September 30, 2007, the Company had $332,753 in cash and cash equivalents. Interest income earned on cash investments during the three and nine months ended September 30, 2007 was $5,174 and $12,018, respectively and is classified as a component of Interest income (expense), net in the Consolidated Statement of Income. Subsequent to the repurchase of Class B shares in the fourth quarter of 2006, the Company ceased making dividend payments.

     During the second quarter of 2007, the Company entered into a revolving credit facility with Bank of America, N.A. that provides up to a maximum of $10,600 to certain of the Company's entities in The People's Republic of China (the "China Credit Facility"). As of September 30, 2007, the outstanding borrowings under the China Credit Facility were $6,389 and are classified within Short-term debt on the Consolidated Balance Sheet. Interest expense is calculated based on the amount borrowed, and for the three and nine month periods ended September 30, 2007, was $81 and $102, respectively. The effective interest rates for the three and nine month periods ended September 30, 2007, were 5.90% and 5.88%, respectively.

     In March 2007, the Company issued $300,000 of Convertible Senior Notes ("Notes"), due March 15, 2027. The net proceeds from the issuance of $292,772, after deducting expenses, are being used to fund business development transactions and for general corporate purposes. Deferred loan costs in the amount of $7,228 are being amortized over seven years.

     On January 23, 2006, the Company paid the balance due on both its 8.625% Senior Notes and 3% Convertible Notes, including principal and accrued interest of $386,251 and call premium in the amount of $18,894. The call premium is included in "Loss on extinguishment of debt" within the Consolidated Statement of Income. In January 2006, the Company repaid all short-term debt outstanding at December 31, 2005, in the amount of $35,713.

6.      Stock-based Compensation

     The Company adopted Statement of Financial Accounting Standards No. 123R ("SFAS 123R"), "Share-Based Payments," effective January 1, 2006. SFAS 123R requires the recognition of the fair value of stock-based compensation in net earnings. Stock-based compensation consists primarily of stock options and restricted stock. Effective in March 2007, the Compensation Committee of the Board of Directors approved the award of equity-related incentives under the Company's 2003 Omnibus Incentive Compensation Plan, which included a new performance-based incentive; called the "Performance Based Restricted Class A Common Stock" ("Performance-Based Restricted Stock") awards. The Performance-Based Restricted Stock units awarded in March and May of 2007 will vest on the date the Company files its first Form 10-K after the performance end date. Any Performance-Based Restricted Stock units awarded after May of 2007 will vest on the later of the third anniversary of the grant date or the date the Company files its first Form 10-K after the performance end date. The final amount of the award will be determined based upon certain financial performance conditions. Executives holding Performance-Based Restricted Stock units will receive between zero and 200% of the target award level based on achieving earnings target levels over a three-year performance period through December 31, 2009. The fair value of the performance-based restricted stock is being amortized to expense over the requisite service period based on achieving 100% of the targeted performance level. Anticipated changes in achieving targeted performance levels will result in changes in estimates of final award levels, and the adjusted fair value of the Performance-Based Restricted Stock will be recognized over the remaining service period.

Stock Options

     The Company estimated the fair value, as of the date of grant, of stock options using the Black-Scholes option pricing model with the following assumptions:

     Black-Scholes assumptions for stock options include the expected volatility of the Company's stock and the expected term of the options. The Company calculates volatility using a weighted average of historical share price volatility. The Company estimates expected life for options by calculating the average of the vesting and expiration periods. The changes in assumptions in 2007 did not have a material effect on results of operations for the three and nine month periods ended September 30, 2007, and reflect the changing profile of the Company since the divestiture of the Generics Business.

     The risk-free interest rates for 2007 and 2006 were based upon U.S. Treasury instrument rates with maturities approximating the expected term of each option grant. The weighted average interest rate in 2007 amounted to 4.53%. The weighted average fair value of options granted during the three and nine months ended September 30, 2007 with exercise prices equal to fair market value on the date of grant was $9.55 and $9.46, respectively.

     Stock options outstanding at September 30, 2007 had an aggregate intrinsic value of $2,334, a weighted average exercise price of $22.91 and a weighted average remaining contractual term of 7.53 years. The number of stock options exercisable at September 30, 2007, was approximately 588,456 shares with an aggregate intrinsic value of $1,831, a weighted average exercise price of $21.27 and a weighted average remaining contractual term of 5.43 years. The total intrinsic value of stock options exercised during the three and nine months ended September 30, 2007 was $67 and $1,816, respectively. The total intrinsic value of stock options exercised during the three and nine months ended September 30, 2006 was $28 and $7,540, respectively.

     As of September 30, 2007, the total remaining unrecognized compensation cost related to non-vested stock options, net of forfeitures, amounted to approximately $5,879. The weighted average remaining requisite service period of the non-vested stock options was approximately 35 months.

Restricted Stock and Performance Based Restricted Stock

     Effective March 28, 2007, the Company granted Performance Based Restricted Stock awards to certain key executives. Compensation for both Performance Based Restricted Stock and restricted stock (collectively, "restricted stock") is recorded based on the market value of the stock on the grant date. The fair value of restricted stock is recorded as deferred compensation (classified as additional paid in capital) at the time of grant, and amortized to expense over the requisite service period. The expense related to restricted stock amounted to $964 and $270 for the three month periods ended September 30, 2007 and 2006, respectively. The expense related to restricted stock amounted to $2,714 and $1,609 for the nine month periods ended September 30, 2007 and 2006, respectively. Total deferred compensation, related to restricted stock amounted to $8,984 and $6,207 at September 30, 2007 and 2006, respectively.

Performance Units

     The Company's 2003 Omnibus Incentive Compensation Plan also provided for the issuance of performance units that were valued based on the Company's Total Shareholder Return as compared to a market index of peer companies and the satisfaction of a free cash flow threshold. Each performance unit had a potential value between zero and $200. In conjunction with the sale of the Generics Business, which made the peer group comparison no longer relevant, the Company froze the performance unit plan effective December 18, 2005. The Company fixed the final payout for each outstanding performance unit at $100 per unit. The value of the performance units, net of forfeitures, will be paid out at the end of the plan's original three year vesting period, December 31, 2007. The total value of performance units outstanding is $2,202, of which $1,931 is accrued at September 30, 2007. The Company recognized expense, net of forfeitures, related to performance units for the three and nine months ended September 30, 2007 in the amounts of $188 and $598, respectively. The Company recognized expense, net of forfeitures, related to performance units for the three and nine months ended September 30, 2006 in the amounts of $841 and $3,626, respectively.

7.      Inventories

     Inventories consist of the following:

   
8.      Long-Term Debt

     On October 26, 2005, the Company entered into a five-year, Senior Secured Credit Facility with Bank of America N.A. consisting of a $175,000 asset-based, revolving loan facility and a $35,000 term loan. The Company used $119,122 of this facility to repay and retire the 2001 U.S. Bank Credit Facility in October 2005. The amounts outstanding under the Senior Secured Credit Facility were subsequently repaid in December 2005 utilizing proceeds from the sale of the Generics Business. In March 2006, the asset-based, revolving loan availability was reduced to $75,000 and the term loan was cancelled. As of September 30, 2007, there were no amounts outstanding under this Facility.

     The Senior Secured Credit Facility, which was amended and restated on March 10, 2006 to reflect the sale of the Generics Business, is secured by the accounts receivable, inventory and certain fixed assets of the U.S. subsidiaries of the Company. The amount that is available to the Company to be borrowed is determined monthly based upon the calculation of a Borrowing Base. The interest rate that the Company would pay on outstanding amounts is based upon a spread over LIBOR or Base Rate. The spread ranges between 1.25% to 2.00% over LIBOR and 0% to 0.50% over the Base Rate. The determination of the spread is based upon the amount of availability under the facility with a lower spread payable based upon greater availability. As long as the Company does not have average availability less than $15,000 over a consecutive 10 day period, there are no financial covenants. In the event that the Company were to breach the availability threshold, the Company would be subject to a minimum Fixed Charge Coverage Ratio of 1:1.

9.   Earnings Per Share

     Basic earnings per share is based upon the weighted average number of common shares outstanding. Diluted earnings per share reflect the dilutive effect of stock options and convertible debt, when appropriate.

     A reconciliation of weighted average shares outstanding from basic to diluted is, as follows:

     The amount of dilution attributable to stock options, determined by the treasury stock method, depends on the average market price of the Company's common stock for each period. For the three months ended September 30, 2007 and 2006, stock options to purchase 710,000 and 927,000 shares, respectively, were not included in the diluted EPS calculation because the option price was greater than the average market price of the Class A common shares. For the nine months ended September 30, 2007 and 2006, stock options to purchase 379,000 and 753,000 shares, respectively, were not included in the diluted EPS calculation because the option price was greater than the average market price of the Class A common shares.

     On December 28, 2006, the Company repurchased all (11,872,897 shares) of its outstanding Class B common shares.

     Intangible assets and accumulated amortization are summarized, as follows:

     Included in the additions is $100,305 related to the September 2007 IBSA License and Distribution Agreements for the exclusive license and distribution rights to market the Flector^® Patch and Tirosint^® gel capsules in the United States (See Note 4).

     The changes in the carrying amount of goodwill attributable to the Company's reportable segments for the nine months ended September 30, 2007 are, as follows:

Additions to goodwill relate to two AH acquisitions in China during the second quarter of 2007 (See Note 3).

11.    Reorganization, Refocus and other Actions

     In connection with the reorganization and refocus of the Company to improve future operations, severance charges associated with workforce reductions and other facility closure and exit costs have been recorded. Severance charges not related to specific programs are not segregated from normal operations. The following table presents activity in the severance and closure and exit costs related accruals for the nine months ended September 30, 2007:

Adjustments recorded during the nine months ended September 30, 2007, relate primarily to the resolution of contractual conditions related to facility closings, revisions to facility exit cost estimates, and asset sales related to previously closed AH facilities.

12.    Pension Plans and Postretirement Benefits

U.S.

     The U.S. pension plan was frozen effective December 31, 2006.

     The net periodic benefit costs for the Company's pension plans and other postretirement plans are as follows:

     The Company expects to contribute approximately $574 to the U.S. pension plans in 2007. Through September 30, 2007, contributions of $162 have been made.

Europe

     The Norwegian pension plan was substantially frozen effective December 31, 2006.

     The net periodic benefit costs for the Company's Norwegian pension plan are, as follows:

     The Company does not expect to make any contributions to the Norwegian pension plan in 2007.

13.      Supplemental Data

     SFAS 130, "Reporting Comprehensive Income" requires foreign currency translation adjustments and certain other items, which were reported separately in stockholders' equity, to be included in Accumulated Other Comprehensive Income (Loss). Included within Accumulated Other Comprehensive Income (Loss) as of September 30, 2007 are foreign currency translation adjustments and previously unrecognized actuarial gains and losses as a result of implementing SFAS No. 158, "Employers' Accounting for Defined Benefit Pension and other Postretirement Plans".

     The components of comprehensive income and accumulated other comprehensive income include:

15.     Business Segment Information

     The Company's businesses are organized in three reportable segments, as follows: Pharmaceuticals ("Pharmaceuticals"), Active Pharmaceuticals Ingredients ("API"), and Animal Health ("AH"). Each business has a segment president who reports to the CEO.

     The operations of each segment are evaluated based on earnings before interest and taxes (operating income). Unallocated costs include corporate expenses for administration, finance, legal and certain unallocated expenses primarily related to stock-based compensation and other long-term incentive compensation, as well as certain costs related to business development activities and the implementation of a company-wide enterprise resource planning system. Segment data includes immaterial inter-segment revenues which are eliminated in the consolidated accounts.

16.     Income Taxes

     The Company's effective tax rate ("ETR") is dependent on many factors including: a.) the impact of enacted tax laws in jurisdictions in which the Company operates; b.) the amount of earnings by jurisdiction, due to varying tax rates in each country; and c.) the Company's ability to utilize various tax losses and credits.

     Based on the Company's assessment of the above factors, the effective tax rates for continuing operations for the three and nine months ended September 30, 2007, were 33% and 35%, respectively. The Company's financial results in the fourth quarter of 2007 will include the $60,000 upfront payment made from Alpharma Ireland to IDEA in October 2007 (See Note 19), for which no tax benefits are expected to be recorded in 2007. As a result, the Company expects its full year 2007 effective tax rate to be significantly higher than prior periods.

     Effective January 1, 2007, the Company adopted FASB Interpretation No. 48, ("FIN 48"), "Accounting for Uncertainty in Income Taxes." As a result of implementing FIN 48, the Company recognized an increase in non-current liabilities of approximately $4,712 for uncertain tax positions which was accounted for as a reduction of beginning Retained Earnings (increase in accumulated deficit). The Company does not expect a significant change in the liabilities recorded for uncertain tax positions in the next twelve months.

     The Company recognizes both interest expense and penalties as part of the related income tax liabilities. During the three and nine month periods ended September 30, 2007, the amount of accrued interest and penalties was not material. At September 30, 2007, the Company had $1,633 of accrued interest and penalties included in non-current liabilities.

17. Contingent Liabilities and Litigation

     The Company is involved in various legal proceedings, of a nature considered normal to its business. It is the Company's policy to accrue for amounts related to these legal matters if it is probable that a liability has been incurred and an amount is reasonably estimable.

     In the opinion of the Company, although the outcome of any legal proceedings cannot be predicted with certainty, the ultimate liability of the Company in connection with the following legal proceedings will not have a material adverse effect on the Company's financial position but could be material to the results of operations or cash flows in any one accounting period.

     The Company is one of multiple defendants that have been named in several lawsuits which allege that one of its AH products causes chickens to produce manure that contains an arsenical compound which, when used as agricultural fertilizer by chicken farmers, degrades into inorganic arsenic and causes a variety of diseases in the plaintiffs (who allegedly live in close proximity to such farm fields). The Company has provided notice to its insurance carriers and its primary insurance carriers have responded by accepting their obligations to defend or pay the Company's defense costs, subject to reservation of rights to later reject coverage for these lawsuits. In addition, one of the Company's carriers has filed a Declaratory Judgment action in state court in which it has sought a ruling concerning the allocation of its coverage obligations to the Company among the Company's several insurance carriers and, to the extent the Company does not have full insurance coverage, to the Company. In addition, this Declaratory Judgment action requests that the Court rule that certain of the carrier's policies provide no coverage because certain policy exclusions allegedly operate to limit its coverage obligations under said policies. Furthermore, the Company's insurance carriers may take the position that some, or all, of the applicable insurance policies contain certain provisions that could limit coverage for future product liability claims arising in connection with such AH product sold on and after December 16, 2003.

     In addition to the potential for personal injury damages to the approximately 152 plaintiffs, the plaintiffs are asking for punitive damages and requesting that the Company be enjoined from the future sale of the product at issue. In September 2006, in the first trial, which was brought by two plaintiffs, the Circuit Court of Washington County, Arkansas, Second Division, entered a jury verdict in favor of the Company. The plaintiffs have appealed the verdict. The court has ruled that future trials are on hold pending the outcome of the appeal. While the Company can give no assurance of the outcome of these matters, it believes that it will be able to continue to present credible scientific evidence that its product is not the cause of any injuries the plaintiffs may have suffered. There is also the possibility of an adverse customer reaction to the allegations in these lawsuits, as well as additional lawsuits in other jurisdictions where the product has been sold. Worldwide sales of this product were approximately $23,000 in 2005, $22,200 in 2006 and $14,900 in the first three quarters of 2007.

     The Company is the subject of tax claims by the Brazilian authorities relating to sales and import taxes which aggregate approximately $10,000. The claims relate to the operations of the Company's AH business in Brazil since 1999. The Company believes it has meritorious defenses and intends to vigorously defend its position against these claims.

     During 2005, the environmental authorities having jurisdiction over the Copenhagen API manufacturing facility gave the Company notice of revised waste discharge levels. The Company believes it has taken the actions necessary to comply with the requirements, including certain plant alterations and modifications at a cost not material to the Company. The environmental authorities have not yet confirmed whether the Company's actions are in compliance with the requirements outlined in the notice.

     In August 2007 the Company paid a reduced criminal fine of $780 in settlement of specified past accidental discharge activities at the Oslo API facility. Separately, in September 2007, the environmental authority having jurisdiction over the Oslo API plant of the Company gave the Company notice that it believes certain ordinary course discharge activities at the facility have not been in compliance with discharge levels permitted under the Company's permit during that period. The Company has responded to the authority's request for further information and indicated it believes it has been in compliance with its permit with respect to its ordinary course discharge activities.

     The failure or inability to comply with applicable regulations could result in further criminal or civil actions affecting production at these facilities which could be materially adverse to the Company.

     On February 28, 2007, the Company received a subpoena from the U.S. Department of Justice requesting certain documents relating to the marketing of Kadian^®. The subpoena did not disclose any allegations underlying this request. The Company is fully cooperating with the U.S. Department of Justice.

     A purported class action lawsuit has been filed with the United States District Court in New Jersey. The complaint alleges that, among other things, (i) over 200 of the Company's U.S. based Pharmaceuticals sales representatives were denied overtime pay, in violation of state and federal labor laws, by being paid for forty hour weeks even though they worked in excess of fifty-five hours per week, and (ii) that the Company violated federal record-keeping requirements. Based upon the facts as presently known, the Company does not believe that it is likely that the class action will result in liability which will be material to the Company's financial position.

     The Company is engaged in disputes with several suppliers, customers and distributors regarding certain obligations with respect to contracts under which the Company obtains raw materials and under which the Company supplies finished products. Given the fact that these disputes will most likely be resolved over more than one year, management does not believe that the disputes in the aggregate will be material to the Company's financial position. However, they could be material to the Company's results of operations or cash flows in the period in which resolution occurs.

     Any further responsibilities for substantially all of the material contingent liabilities related to the Generics Business have been transferred to Actavis or entities owned by Actavis, subject to certain representations or warranties made by the Company to Actavis as a part of the transaction to the extent such representations and warranties were incorrect. The Company has retained certain specified liabilities which it believes are not material to the Company and, it is possible that the Company may be held responsible for certain liabilities of the Generics Business transferred to Actavis in the event Actavis fails or is unable to satisfy such liabilities.

     The Company and its subsidiaries are, from time to time, involved in other litigation arising out of the ordinary course of business. It is the view of management, after consultation with counsel, that the ultimate resolution of all other pending suits on an individual basis should not have a material adverse effect on the consolidated financial position, results of operations or cash flows of the Company.

18. Recent Accounting Pronouncements

     Proposed FASB Staff Position (FSP) number APB 14-a, "Accounting for Convertible Debt Instruments that may be Settled in Cash upon Conversion (Including Partial Cash Settlement)", was issued for comments with a comment deadline of October 15, 2007. If adopted, it will be effective for companies with fiscal years beginning after December 15, 2007, with retrospective application. Early adoption is not permitted. FSP APB 14-a specifies that issuers of convertible debt instruments should separately account for the liability and equity components in a manner that will reflect the entity's nonconvertible debt borrowing rate when interest cost is recognized in subsequent periods.

     If FSP number APB 14-a is adopted, the Company's accounting for its $300,000 Convertible Senior Notes (the "Notes") will be impacted. The Company is currently evaluating the potential impact; but estimates that implementation would result in an approximately $80,000 reduction in its March 31, 2007 Note balance outstanding, with a corresponding increase in equity. The Company also estimates that if adopted, the 2008 and retrospective 2007 application of the standard would result in increased interest expense of approximately $10,000 and $7,000 for the years ending 2008 and 2007, respectively.

     In September 2006, the FASB issued Statement of Financial Accounting Standards No. 157, "Fair Value Measurements" ("SFAS 157"). SFAS 157 establishes a framework for measuring fair value under generally accepted accounting principles ("GAAP") in the United States and will be applied to existing accounting and disclosure requirements in GAAP that are based on fair value. SFAS 157 does not require any new fair value measurements. SFAS 157 emphasizes a "market-based" as opposed to an "entity-specific" measurement perspective, establishes a hierarchy of fair value measurement methods and expands disclosure requirements about fair value measurements including methods and assumptions and the impact on earnings. The Company is evaluating the potential impact of SFAS 157, which is to be adopted effective January 1, 2008, and applied prospectively.

     In February 2007, the FASB issued Statement of Financial Accounting Standards No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities - Including an amendment of FASB Statement No. 115" ("SFAS 159"). SFAS 159 provides an option to report certain financial assets and liabilities at fair value primarily to reduce the complexity and level of volatility in the accounting for financial instruments resulting from measuring related financial assets and liabilities differently under existing U.S. GAAP. SFAS 159 is effective January 1, 2008. The Company is evaluating the potential impact of SFAS 159.

19. Subsequent Event

     In October 2007, the Company's affiliate, Alpharma Ireland Limited ("Alpharma Ireland"), closed on an agreement with IDEA AG ("IDEA"), a privately held biopharmaceutical company with headquarters in Munich, Germany. The agreement provides the Company with an exclusive license to the United States rights to ketoprofen in Transfersome^® gel, a prescription topical non-steroidal anti-inflammatory drug ("NSAID") in Phase III clinical development.

     The terms of the license agreement between Alpharma Ireland and IDEA include a $60,000 payment that was made in connection with the October 2007 closing. The agreement also includes three clinical and regulatory progress milestone payments ("progress milestone payments") totaling $77,000 that are expected to be paid over the next 15 months, based upon IDEA's achievement of contractually-specified conditions. An additional milestone payment of either $45,000 or $65,000 is conditioned on U.S. product approval (with the higher amount dependent upon the achievement of a specified end point in one of the clinical trials).

     IDEA has agreed to pay the costs of specified studies it is undertaking to obtain FDA approval of ketoprofen in Transfersome^® gel. Under the terms of the agreement, if both the first and second progress milestone payments totaling $37,000 are not paid to IDEA by January 1, 2008, IDEA has the option, during the period January 1, 2008 to December 31, 2009, to receive a loan of up to $20,000 from Alpharma Ireland in support of its clinical development program. Any outstanding loan amounts will become due and payable by IDEA immediately upon its receipt of both the first and second progress milestone payments. All outstanding loan amounts will bear interest at a rate of one month LIBOR plus 1.5% and, if not due earlier, will be due on December 31, 2009.

     The terms of the agreement also include the issuance of two series of stock warrants to IDEA for the purchase of shares of the Company's Class A common stock. Both series vest only upon FDA approval of the product in the United States. The amount and pricing of the Phase III Milestone ("Series A") warrants are tied to positive phase III results, and the Form of Approval ("Series B") warrants are tied to FDA approval. The strike price for the Series A warrants will be determined by applying a 50% premium to the 30 day average stock price immediately preceding the announcement of positive phase III results; with a minimum exercise price per share of $22.50. The strike price for the Series B warrants will be determined by applying a 25% premium to the 30 day average stock price immediately following the FDA approval date; with a minimum exercise price per share of $18.75. For both the Series A and B warrants, the number of shares eligible to be purchased under the warrants will be determined by dividing $50,000 for each series by the respective strike price for each series. Upon vesting at the time of FDA approval, both series of warrants have a term of approximately five years, with a limit of ten years from the date of entering into the agreement.

     The agreement includes commitments whereby the Company is required to spend pre-determined minimum amounts for the commercialization of the product, (including selling, marketing and medical educational expenses) during the first four years following the product's launch.

     The agreement also includes the future payment of royalties based on annual net sales applied to a tiered structure. The Company's royalty payments to IDEA will be calculated starting at 5% of annual net sales of the product up to a maximum royalty rate of 24%, based upon contractually agreed annual net sales levels.

     The license agreement expires upon the later of the expiration of all U.S. patent rights licensed by IDEA to Alpharma Ireland or 2029.

     In connection with the closing in October 2007, Alpharma Ireland paid $60,000 to IDEA and issued both series of stock warrants. In addition, during the third quarter of 2007, the Company recorded approximately $1,900 in transaction-related costs.

Item 2.     Management's Discussion and Analysis of Financial Condition and Results of Operations
(In millions, except per share data)

Overview

     The Company is a global specialty pharmaceutical company that develops, manufactures and markets pharmaceutical products for humans and animals. The Company's businesses are organized in three business segments. The Company currently markets one branded human pharmaceutical prescription product that is contract manufactured by a third party, an extended release morphine sulfate pain medication sold under the trademark Kadian^®, in the U.S. and is in the process of developing, commercializing, and launching a series of other products over the next few years. The Company manufactures and markets a line of fermentation-based active pharmaceutical ingredients ("APIs") that are used primarily by third parties in the manufacturing of generic and branded pharmaceutical products. It also manufactures and markets animal health products in various formulations and dosage forms.

     In October 2007, the Company's affiliate, Alpharma Ireland Limited, closed on an agreement with IDEA AG, to license the exclusive U.S. rights to ketoprofen in Transfersome® gel, a prescription topical non-steroidal anti-inflammatory drug ("NSAID") in Phase III clinical development (See Note 19).

     In September 2007, the Company's affiliate, Alpharma Pharmaceuticals LLC, closed on two license and distribution agreements with Institut Biochimique SA ("IBSA") to market two FDA approved products in the United States: the Flector^® Patch and Tirosint^® gel capsules (See Note 4).

     On December 19, 2005, the Company sold its worldwide human generic pharmaceutical business (the "Generics Business") to Actavis Group hf ("Actavis") for $810 million in cash. On March 31, 2006, the Company completed the sale of its generic telemarketing distribution business, ParMed Pharmaceuticals, Inc. ("ParMed") for $40.1 million in cash. Both the Generics Business and ParMed are classified as discontinued operations in the Consolidated Financial Statements (See Note 2 to the Consolidated Financial Statements).

The Company's business segments are defined, as follows:

     Total revenues increased 6.4% for the quarter ended September 30, 2007 compared to the same quarter of 2006. Operating income was $19.7 million in the third quarter of 2007 compared to $22.2 million in 2006. Diluted earnings (loss) per share was $0.34 in 2007 compared to $0.31 in 2006.

The following summarizes revenues and operating income by segment:

Revenues:

     Pharmaceuticals revenues increased $7.7 million, or 22.2%, to $42.4 million in the third quarter of 2007, compared to $34.7 million in 2006. The revenue growth was principally attributable to increased volumes driven by script growth and higher year-over-year pricing.

     Revenues in API of $42.6 million were consistent with third quarter 2006 levels. Increased vancomycin volumes and favorable foreign exchange were offset by lower volumes of certain other products.

     AH revenues increased $2.9 million, or 3.3%, to $90.8 million compared to $87.9 in the third quarter of 2006. Translation of revenues into the U.S. dollar increased AH revenues by approximately $1.5 million in comparison to the third quarter of 2006. Excluding the year-over-year effects of currency, AH revenues increased 1.6% versus the prior year. The increase in revenues reflects revenue gains in the European and Latin American markets.

Gross Profit:

     On a Company-wide basis gross profit in the third quarter of 2007 increased $4.4 million compared to the third quarter of 2006. Excluding a one time favorable settlement of a contract dispute in the AH business of $1.1 million, gross profit increased $3.3 million. As a percentage of sales overall gross profit margin was 56.3% in 2007, versus 57.2% in 2006. The majority of the year-over-year decline in gross profit margin was attributable to the unfavorable effects of currency.

   
Operating Expenses:

     On a consolidated basis, selling, general and administrative ("SG&A") expenses in the third quarter of 2007 increased $0.7 million as compared to the third quarter of 2006. Excluding a favorable settlement of a contract dispute in the AH business of $1.6 million, SG&A expenses increased $2.3 million. Foreign exchange had an unfavorable impact of $1.8 million in the year-over-year change in SG&A expenses. The remainder of the increase principally relates to additional operational infrastructure to support growth initiatives in the Pharmaceuticals and API businesses, partially offset by lower corporate and unallocated expenses. As a percentage of revenues, SG&A expense declined from 37.0% in the third quarter of 2006 to 35.2% in 2007.

     Research and development expenses increased $6.5 million in the third quarter of 2007 in comparison to 2006, due primarily to spending for clinical trials related to abuse-deterrent opioid product development programs in Pharmaceuticals. As a percentage of revenues, R&D expense amounted to 10.0% in 2007 versus 6.7% for the three months ended September 30, 2006.

     Asset impairments and other (income) expense amounted to income of $0.3 million in the third quarter of 2007, consisting principally of facility exit cost adjustments related to previously closed AH facilities.

Operating Income:

     Operating income ("OI") decreased by $2.5 million. The change in operating income is summarized as follows:

Interest Income (Expense), net:

     The Company reported net interest income of $3.0 million for the third quarter of 2007 compared to $4.4 million of interest income in last year's third quarter. An analysis of the components of interest income (expense), net is, as follows:

Other Income (Expense), net:

     A detail of Other income (expense), net follows:

Tax Provision

     The Company's effective tax rate ("ETR") is dependent on many factors including: a.) the impact of enacted tax laws in jurisdictions in which the Company operates; b.) the amount of earnings by jurisdiction, due to varying tax rates in each country; and c.) the Company's ability to utilize various tax losses and credits.

     Based on the Company's assessment of the above factors, the effective tax rates for continuing operations for the three and nine months ended September 30, 2007, were 33% and 35%, respectively. The Company's financial results in the fourth quarter of 2007 will include the $60 million upfront payment made from Alpharma Ireland to IDEA in October 2007 (See Note 19), for which no tax benefits are expected to be recorded in 2007. As a result, the Company expects its full year 2007 effective tax rate to be significantly higher than prior periods.

The following summarizes revenues and operating income by segment:

Revenues:

     Pharmaceuticals revenues increased $15.9 million, or 15.3%, to $119.5 million in the first nine months of 2007 compared to $103.6 million in 2006. The revenue growth was principally attributable to increased volumes driven by script growth, higher year-over-year pricing, and the launch of an additional dosage strength (new line extensions) of Kadian^®.

     Revenues in API increased $11.0 million, or 8.6%, to $138.7 million compared to $127.7 million in the first nine months of 2006. A small portion of API revenues are denominated in currencies other than the U.S. dollar. Translation of these revenues into the U.S. dollar increased API revenues by approximately $2.5 million in comparison to the first nine months of 2006. Excluding the year-over-year effects of currency, API revenues increased 6.7% versus the prior year. The revenue increase was primarily attributable to increased volumes,

principally related to vancomycin.
    

     AH revenues increased $12.9 million, or 5.1% versus the first nine months of 2006. Translation of revenues into the U.S. dollar increased AH revenues by approximately $4.2 million in comparison to the first nine months of 2006. Excluding the year-over-year effects of currency, AH revenues increased 3.4% versus the first nine months of 2006. The increase in revenues was due primarily to higher volumes in both U.S. poultry and livestock, as well as increased revenues in the European and Latin American markets.

Gross Profit:

     On a Company-wide basis gross profit increased $13.0 million in 2007 compared to the same period of 2006. As a percentage of sales, overall gross profit margin was 57.3% in 2007, versus 59.3% in 2006, with the decline principally attributable to the unfavorable effects of currency, lower year-over-year pricing in API, and higher production costs in API and AH, primarily for raw materials and energy.

   
Operating Expenses:

     On a consolidated basis, selling, general and administrative ("SG&A") expenses increased $6.5 million in 2007 as compared to 2006. Foreign exchange had an unfavorable impact of $4.4 million on the year-over-year change in SG&A expenses. The remainder of the dollar increase principally relates to higher volume and additional operational infrastructure to support growth initiatives in all three businesses, partially offset by lower corporate and unallocated expenses. As a percentage of revenues, SG&A expenses decreased from 38.6% in 2006 to 36.9% in 2007.

     Research and development expenses increased $28.6 million in the first nine months of 2007 compared to 2006, due primarily to spending related to clinical trials related to abuse-deterrent opioid product development programs in Pharmaceuticals. Also included in 2007 research and development expenses are year to date payments of $2.0 million under an exclusive licensing agreement with Tris Pharma, Inc., whereby the Company will gain access to a proprietary drug delivery platform. As a percentage of revenues, R&D expenses amounted to 10.7% in 2007 versus 5.7% for the nine months ended September 30, 2006.

     Asset impairments and other (income) expense amounted to income of $3.3 million for the nine months ended September 30, 2007 and pertained to facility exit cost adjustments and asset sales related to previously closed AH facilities.

Operating Income:

     Operating income decreased by $18.8 million. The change in operating income is summarized as follows:

Interest Income (Expense), net:

     The Company reported net interest income of $7.7 million for the first three quarters of 2007 compared to $11.2 million of net interest income in the comparable period last year. Interest expense in 2007 includes interest on the $300 million Convertible Senior Notes issued in March 2007. An analysis of the components of interest income (expense), net is, as follows:

Loss on Extinguishment of Debt:

     Results for the nine months ended September 30, 2006 include the payment of a call premium of $18.9 million and write-offs of deferred loan costs of $0.5 million associated with the repayment of the Company's outstanding long-term debt in January 2006.

Other Income (Expense), net:

     A detail of Other income (expense), net follows:

Tax Provision

     The Company's effective tax rate ("ETR") is dependent on many factors including: a.) the impact of enacted tax laws in jurisdictions in which the Company operates; b.) the amount of earnings by jurisdiction, due to varying tax rates in each country; and c.) the Company's ability to utilize various tax losses and credits.

     Based on the Company's assessment of the above factors, the effective tax rates for continuing operations for the three and nine months ended September 30, 2007, were 33% and 35%, respectively. The Company's financial results in the fourth quarter of 2007 will include the $60 million upfront payment made from Alpharma Ireland to IDEA in October 2007 (See Note 19), for which no tax benefits are expected to be recorded in 2007. As a result, the Company expects its full year 2007 effective tax rate to be significantly higher than prior periods.

     In July 2006, the Financial Accounting Standards Board issued FIN 48, Accounting for Uncertainty in Income Taxes which became effective for the Company, January 1, 2007. FIN 48 addresses the determination of how tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under FIN 48, the Company must recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. The impact of the Company's reassessment of its tax positions in accordance with FIN 48 did not have a material impact on results of operations, financial condition or liquidity.

     At September 30, 2007, the Company had $332.8 million in cash and cash equivalents. Interest income earned on investments was $12.0 million for the first nine months of 2007 and is classified as a component of Interest income (expense), net in the Consolidated Statements of Income.

     In March 2007, the Company issued $300 million of Convertible Senior Notes, due March 2027. The net proceeds from the issuance, after deducting expenses, were $292.8 million. The net proceeds are being used to fund business development transactions and for general corporate purposes.

     Cash flow from operations for the nine months ended September 30, 2007 was $66.0 million, compared to $5.1 million provided from operations in the first nine months of 2006. During the first nine months of 2007, the Company received net cash tax refunds of $2.7 million versus $45.6 million paid for cash taxes in the first nine months of 2006, which is included in the overall change.

     Cash flow used in investing activities for the first nine months of 2007 included $100.3 million related to the Company's licensing agreement with IBSA and $6.9 million related to the Company's acquisitions in China (See Notes 3 and 4). Cash flow used in investing activities also included capital expenditures of $41.8 million, of which approximately $6.9 million related to the manufacturing alliance with Hisun (See Note 3). Cash flow provided by investing activities for the first nine months of 2006 included the proceeds from the sale of ParMed of $40.1 million.

     The cash flow provided by financing activities in the first nine months of 2007 was $305.1 million compared with a use of $429.4 million last year. Cash flow from financing activities in the first nine months of 2007 includes the net proceeds ($292.8 million) from the issuance of $300 million in Convertible Senior Notes and net proceeds ($6.4 million) from a revolving credit facility for the Company's entities in The People's Republic of China. The use of funds in 2006 included $436.3 million related to the repayment of debt, including a call premium of $18.9 million.

     Working capital at September 30, 2007, was $443.5 million compared to $198.0 million at December 31, 2006. Working capital is defined as current assets less current liabilities. The increase in working capital is primarily related to the $292.8 million of cash received in conjunction with the issuance of Convertible Senior Notes in March 2007. In addition to the increase in cash, the increase in current assets reflects increases in inventory levels as a result of higher volumes and supply chain planning in anticipation of expected increased market demand for certain products.

    Stockholders' equity at September 30, 2007 was $777.7 million compared to $724.0 million at December 31, 2006. The increase in Stockholders' Equity in 2007 resulted primarily from net earnings for the first nine months of 2007. The accumulated deficit decreased by $35.3 million reflecting first three quarters net earnings, partially offset by the impact ($4.7 million) of the implementation of FIN 48. At September 30, 2007, due primarily to the cumulative weakening of the U.S. dollar against many other currencies, the Company reported Accumulated Other Comprehensive Income of $65.8 million compared to $58.2 million at December 31, 2006.

     Quantitative and Qualitative Disclosure - This information is included in Item 7a of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006.

(a) Evaluation of Disclosure Controls and Procedures

     The Company has implemented and maintains disclosure controls and procedures designed to ensure that information required to be disclosed in reports the Company files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's President and Chief Executive Officer ("CEO") and Executive Vice President and Chief Financial Officer ("CFO") as appropriate to allow timely decisions regarding disclosure. The disclosure controls and procedures involve participation by various individuals in the Company having access to material information relating to the operations of the Company. It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events.

     The Company's CEO and CFO completed an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Exchange Rule 13a-15 as of September 30, 2007. Based on this evaluation, they concluded that the Company's disclosure controls and procedures were effective as of September 30, 2007.

(b) Changes in Internal Control Over Financial Reporting

----------

Statements made in this Form 10-Q, are forward-looking statements made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward looking statements. Information on other important potential risks and uncertainties not discussed herein may be found in the Company's filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2006.

PART II. OTHER INFORMATION

     See Note 17 to the Company's Consolidated Financial Statements included in Part 1 of this Report for a discussion of material developments in the Company's legal proceedings.

     In addition to the other information set forth in this Report, you should carefully consider the factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for our fiscal year ended December 31, 2006. The risks discussed in our Annual Report on Form 10-K could materially affect our business, financial condition and future results. The risks described in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition or operating results. There have been no material changes in our risk factors other than as described below.

     The Company's future success is largely dependent upon its ability to develop, manufacture and market commercially successful new products. Generally, the successful commercial marketing of the Company's products depends on completing the following steps in a time frame to allow the Company to be among the first to market a particular product:

• developing and testing the product;

• proving that the product is safe and effective; and

• filing for and receiving regulatory approvals to manufacture and sell the product in a timely manner.

     Through its Exclusive License Agreement with IDEA AG, which closed in October 2007, the Company's subsidiary, Alpharma Ireland Limited, agreed that IDEA AG will conduct the clinical development and testing of its licensed product candidate, ketoprofen in Transfersome^® gel in order to obtain FDA approval for it. The prospects and timing of FDA approval of ketoprofen in Transfersome^® gel will depend, in large part, upon the efforts of IDEA AG in executing the mutually agreed clinical and regulatory plan. There can be no assurance that ketoprofen in Transfersome^® gel will ever be approved by the FDA, in which case, the Company would receive no return on its investment in the product candidate.

     Delays in the development, manufacture or marketing of new products will impact the Company's expenses and revenues. The Company cannot be sure that any product presently going through the process set forth above, or which may be chosen by the Company to enter this process in the future, will result in the timely and profitable commercial launch of a new product.

A delay in or the failure to launch Flector^® Patch, Tirosint^® and Kadian^® NT could be materially adverse to the Company's operations.

     In connection with its Exclusive License and Distribution Agreements, dated August 16, 2007, with IBSA (the "IBSA Agreements"), the Company's subsidiary, Alpharma Pharmaceuticals LLC ("Alpharma Pharmaceuticals"), has made substantial investments with respect to its Flector^® Patch and Tirosint^® products, including scaling up its sales force and other infrastructure as well as the payment of a $100 million upfront fee in order to obtain the rights to these products. The IBSA Agreements also set out required time periods within which Alpharma Pharmaceuticals must launch each of the products and certain requirements for Alpharma Pharmaceuticals to purchase a minimum amount of the products from IBSA. The Company's failure to launch these products or comply with the minimum purchase requirements according to the time line set forth in the IBSA Agreements could materially adversely affect the Company's financial results and operations.

     The Company intends to continue to pursue product-specific licensing, marketing agreements, co-development opportunities and other partnering arrangements. The Company may also pursue selective product and company acquisitions. The Company cannot be sure that it will be able to locate suitable partners for these transactions. In addition, assuming the Company identifies suitable partners, the process of effectively entering into these arrangements involves risks that the Company's management's attention may be diverted from other business concerns and that the Company may have difficulty integrating the new arrangements into its existing business. In addition, certain transactions could adversely impact earnings as the Company incurs development and other expenses related to the transactions and the Company could incur debt to complete these transactions. Debt instruments could contain contractual commitments and covenants that could adversely affect the Company's cash flow and its ability to operate its business.

     Additionally, certain of the Company's partners, such as IBSA, have entered into arrangements with third parties relating to supply of the Company's products. The Company does not have any control over such third party arrangements.

     During 2005, the environmental authorities having jurisdiction over the Copenhagen API manufacturing facility gave the Company notice of revised waste discharge levels. The Company believes it has taken the actions necessary to comply with the requirements, including certain plant alterations and modifications at a cost not material to the Company. The environmental authorities have not yet confirmed whether the Company's actions are in compliance with the requirements outlined in the notice.

     In August 2007 the Company paid a reduced criminal fine of $780 in settlement of specified past accidental discharge activities at the Oslo API facility. Separately, in September 2007, the environmental authority having jurisdiction over the Oslo API plant of the Company gave the Company notice that it believes certain ordinary course discharge activities at the facility have not been in compliance with discharge levels permitted under the Company's permit during that period. The Company has responded to the authority's request for further information and indicated it believes it has been in compliance with its permit with respect to its ordinary course discharge activities.

     The failure or inability to comply with applicable regulations could result in further criminal or civil actions affecting production at these facilities which could be materially adverse to the Company.

     On October 25, 2007, the Alpharma Inc. Change in Control Plan was amended (i) to provide new definitions that are compliant with Section 409A of the Code, and (ii) to set forth the method for determining "specified employees".

     On October 25, 2007, the Alpharma Inc. Severance Plan was amended (i) to provide new definitions that are compliant with Section 409A of the Code, and (ii) to set forth the method for determining "specified employees".

(a)     Exhibits

* Portions of this Exhibit have been omitted pursuant to a request for confidential treatment.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.